AMBIGUOUS RESULTS

Veru's enobosarm preserves lean mass with GLP-1 in Phase 2b, but posts no numbers

The QUALITY trial reported lean-mass and fat-loss benefits with enobosarm plus semaglutide in older adults, yet Veru disclosed no effect size, p-value, or safety data.

By AppliedXLJuly 7, 2026Trial NCT06282458

Executive Summary

Veru reported that adding enobosarm to semaglutide preserved lean mass and physical function while producing greater fat loss than semaglutide alone, but the disclosure carried no effect sizes or statistical tests.
The claimed benefit lines up with the trial's own registered primary endpoint, lean body mass change from baseline, giving the result a direct tie to what the study was designed to measure.
Veru is carrying the same combination into a larger, ongoing Phase 2b trial with DEXA-based interim data expected in early 2027 and final topline data due by the end of 2027.
No other industry-sponsored trial combines an androgen receptor modulator with a GLP-1 for muscle preservation in older adults, leaving Veru's approach without a direct peer to benchmark against.

The disclosure

Veru Inc. said its Phase 2b QUALITY study, a randomized, placebo-controlled trial testing enobosarm plus semaglutide against semaglutide alone in adults 60 and older with obesity, produced preservation of lean mass and physical function alongside greater fat loss during the 16-week active weight-loss period. Total weight loss was similar across arms at 16 weeks. The trial completed with 168 patients enrolled, matching its target, and finished under the NCT06282458 registry record. Veru+1

Probability of Success

Endpoint Met97%

Completes99%

Clinical Significance21%

Regulatory78%

What the endpoint measures

The registered primary endpoint is the percentage change from baseline in total lean body mass at 112 days, measured by DEXA scan, with percent change in total fat mass as a secondary measure. The July 2026 disclosure of preserved lean mass and greater fat loss speaks directly to that endpoint structure, but Veru did not publish the percentage change, a confidence interval, or a p-value for either measure, and safety data were not reported. NCT06282458+1

Timing

Veru first guided to topline results by calendar year-end 2024 when the trial began enrolling in April 2024. The trial's primary completion date registered as April 11, 2025, and the study reached Completed status in September 2025, with enrollment updated from 150 to 168 at that point. The July 7, 2026 disclosure of results came roughly a year and a half after the original guidance and about ten months after the trial's own completion date. Veru+2

The competitive frame

No other industry trial pairs an androgen receptor modulator with a GLP-1 receptor agonist specifically to preserve muscle in older adults on weight-loss therapy, leaving the QUALITY design without a direct comparator in that combination. The broader androgen receptor drug class is active mainly in prostate cancer, where compounds including darolutamide, apalutamide, and enzalutamide are tested as receptor antagonists rather than the selective modulator approach enobosarm uses, so those programs inform target biology without competing on the muscle-preservation question this trial tests. NCT06282458

Next test

Veru is enrolling roughly 200 patients age 65 and older in a follow-on Phase 2b trial called PLATEAU, testing the same enobosarm-semaglutide combination on total body weight, fat mass, lean mass, physical function, and bone mineral density over 68 weeks. An interim DEXA-based analysis of lean and fat mass is expected at 32 weeks in the first quarter of 2027, with final topline data expected in the fourth quarter of 2027. That trial's primary endpoint is percent change in total body weight at 68 weeks, a different and longer-duration bar than the QUALITY trial's 112-day lean-mass endpoint. Veru

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.